Mechanisms of estrogen-induced venous thromboembolism

Mutation in blood coagulation factor V associated with resistance to activated protein C

Bertina, R. M., Koeleman, B. P. C., Koster, T., Rosendaal, F. R., Dirven, R. J., de Ronde, H., van der Velden, P. A., & Reitsma, P. H. (1994) · Nature · doi:10.1038/369064a0 · Cited by 3,769 · see citing works

A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis

Poort, S., Rosendaal, F. R., Reitsma, P. H., & Bertina, R. M. (1996) · Blood · doi:10.1182/blood.v88.10.3698.bloodjournal88103698 · Cited by 3,064 · see citing works

Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.

Dahlbäck, B., Carlsson, M., & Svensson, P. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.3.1004 · Cited by 1,986 · see citing works

Venous thrombosis: a multicausal disease

Rosendaal, F. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10266-0 · Cited by 1,584 · see citing works

Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study

Koster, T., Vandenbroucke, J. P., Rosendaal, F. R., de Ronde, H., Briët, E., & Bertina, R. M. (1993) · The Lancet · doi:10.1016/s0140-6736(05)80081-9 · Cited by 1,236 · see citing works

Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation

Vandenbroucke, J. P., Koster, T., Rosendaal, F. R., Briët, E., Reitsma, P. H., & Bertina, R. M. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90286-0 · Cited by 1,063 · see citing works

Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen components

Jick, H., Jick, S. S., Myers, M. W., Vasilakis‐Scaramozza, C., & Gurewich, V. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91928-7 · Cited by 721 · see citing works

High Levels of Coagulation Factor XI as a Risk Factor for Venous Thrombosis

Meijers, J. C. M., Tekelenburg, W. L. H., Bouma, B. N., Bertina, R. M., & Rosendaal, F. R. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003093421004 · Cited by 699 · see citing works

The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study

Vlieg, A. V. H., Helmerhorst, F. M., Vandenbroucke, J. P., Doggen, C. J. M., & Rosendaal, F. R. (2009) · BMJ · doi:10.1136/bmj.b2921 · Cited by 661 · see citing works

Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease

World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1995) · The Lancet · doi:10.1016/s0140-6736(95)91927-9 · Cited by 453 · see citing works

Different Risks of Thrombosis in Four Coagulation Defects Associated With Inherited Thrombophilia: A Study of 150 Families

Martinelli, I., Mannucci, P. M., Stefano, V. D., Taioli, E., Rossi, V., Crosti, F., Paciaroni, K., Leone, G. G. M., & Faioni, E. M. (1998) · Blood · doi:10.1182/blood.v92.7.2353 · Cited by 441 · see citing works

High levels of factor IX increase the risk of venous thrombosis

Vlieg, A. V. H., van der Linden, I. K., Bertina, R. M., & Rosendaal, F. R. (2000) · Blood · doi:10.1182/blood.v95.12.3678 · Cited by 403 · see citing works

Oral Contraceptive Estrogen Dose and the Risk of Deep Venous Thromboembolic Disease

Gerstman, B. B., Piper, J. M., Tomita, D. K., Ferguson, W., Stadel, B. V., & Lundin, F. E. (1991) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115799 · Cited by 349 · see citing works

Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives

Rosing, J., Tans, G., Nicolaes, G. A. F., Thomassen, M. C. L. G. D., Van Oerle, R., Van DerPloeg, P. M. E. N., Heijnen, P., Hamulyak, K., & Hemker, H. C. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.192707.x · Cited by 325 · see citing works

Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.

Farley, T., Meirik, O., Cl, C., Marmot, M. G., & Poulter, N. R. (1995) · PubMed · Cited by 319 · see citing works

Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive

van den Heuvel, M. W., van Bragt, A. J. M., Alnabawy, A., & Kaptein, M. C. J. (2005) · Contraception · doi:10.1016/j.contraception.2005.03.005 · Cited by 319 · see citing works

VENOUS THROMBOEMBOLIC DISEASE AND ABO BLOOD TYPE

Jick, H., Westerholm, B., Vessey, M., Lewis, G., Slone, D., Inman, W. W., Shapiro, S., & Worcester, J. (1969) · The Lancet · doi:10.1016/s0140-6736(69)91955-2 · Cited by 317 · see citing works

A Reduced Sensitivity for Activated Protein C in the Absence of Factor V Leiden Increases the Risk of Venous Thrombosis

de Visser, M. C. H., Rosendaal, F. R., & Bertina, R. M. (1999) · Blood · doi:10.1182/blood.v93.4.1271 · Cited by 311 · see citing works

Genetics of venous thrombosis

Rosendaal, F. R., & Reitsma, P. H. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03394.x · Cited by 292 · see citing works

New Light on Carcinoid Flush

Beavan, T. E. D. (1964) · The Lancet · doi:10.1016/s0140-6736(64)92923-x · Cited by 283 · see citing works

Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives

World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception∗Appendix e (1998) · Contraception · doi:10.1016/s0010-7824(98)00041-9 · Cited by 258 · see citing works

Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study

Rosing, J., Middeldorp, S., Curvers, J., Thomassen, S., Nicolaes, G. A. F., Meijers, J. C. M., Bouma, B. N., Buller, H. R., Prins, M. H., & Tans, G. (1999) · The Lancet · doi:10.1016/s0140-6736(99)06092-4 · Cited by 257 · see citing works

Coagulation factors and the protein C system as determinants of thrombin generation in a normal population

Dielis, A. W. J. H., Castoldi, E., Spronk, H. M. H., van Oerle, R., Hamulyák, K., Cate, H. T., & Rosing, J. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02824.x · Cited by 250 · see citing works

Changes in the plasma levels of vitamin K‐dependent proteins C and S and of C4b‐binding protein during pregnancy and oral contraception

Malm, J., Laurell, M. H., & Dahlbäck, B. (1988) · British Journal of Haematology · doi:10.1111/j.1365-2141.1988.tb04232.x · Cited by 250 · see citing works

Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis

Dahm, A. E. A., Vlieg, A. V. H., Bendz, B., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3188 · Cited by 243 · see citing works

Activated Protein C Resistance and Factor V Leiden Mutation Are Independent Risk Factors for Venous Thromboembolism

Rodeghiero, F., & Tosetto, A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-8-199904200-00004 · Cited by 232 · see citing works

Effects of Protein S and Factor Xa on Peptide Bond Cleavages during Inactivation of Factor Va and Factor VaR506Q by Activated Protein C

Rosing, J., Hoekema, L., Nicolaes, G. A. F., Thomassen, S., Hemker, H. C., Váradi, K., Schwarz, H. P., & Tans, G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27852 · Cited by 230 · see citing works

PULMONARY EMBOLISM

Jordan, W. M., & ANAND, J. K. (1961) · The Lancet · doi:10.1016/s0140-6736(61)91061-3 · Cited by 225 · see citing works

Effects on Coagulation of Levonorgestrel- and Desogestrel-containing Low Dose Oral Contraceptives: a Cross-over Study

Meijers, J. C. M., van den Ende, A., van Enk, A., Bouma, B. N., Tans, G., Rosing, J., Prins, M. H., Buller, H. R., & Middeldorp, S. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613958 · Cited by 217 · see citing works

Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects

Bloemenkamp, K. W. M., Rosendaal, F. R., Helmerhorst, F. M., & Vandenbroucke, J. P. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.1.49 · Cited by 213 · see citing works

A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways

Tans, G., Curvers, J., Middeldorp, S., Thomassen, M. C., Prins, M., Bouma, B., Büller, H., Meijers, J., & Rosing, J. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613960 · Cited by 203 · see citing works

Risk of idiopathic venous thromboembolism in users of progestagens alone

Vasilakis, C., Jick, H., & Melero-Montes, M. D. M. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04394-9 · Cited by 194 · see citing works

Venous Thromboembolism, Myocardial Infarction, and Stroke Among Transdermal Contraceptive System Users

Cole, J. A., Norman, H. S., Doherty, M., & Walker, A. M. (2007) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000250968.82370.04 · Cited by 191 · see citing works

Drospirenone: a Novel Progestogen with Antimineralocorticoid and Antiandrogenic Activity

Muhn, P., Fuhrmann, U., Fritzemeier, K. H., Krattenmacher, R., & Schillinger, E. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb31386.x · Cited by 184 · see citing works

Comparative Pharmacology of Newer Progestogens

Kühl, H. (1996) · Drugs · doi:10.2165/00003495-199651020-00002 · Cited by 171 · see citing works

Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives

Vasilakis‐Scaramozza, C., & Jick, H. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06522-9 · Cited by 162 · see citing works

Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial

Kemmeren, J. M., Algra, A., Meijers, J. C. M., Tans, G., Bouma, B. N., Curvers, J., Rosing, J., & Grobbee, D. E. (2004) · Blood · doi:10.1182/blood-2003-04-1285 · Cited by 157 · see citing works

Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?

Odlind, V., Milsom, I., Persson, I. R., & Victor, A. (2002) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1034/j.1600-0412.2002.810603.x · Cited by 156 · see citing works

Increased Fibrinolytic Activity during Use of Oral Contraceptives Is Counteracted by an Enhanced Factor XI-independent down Regulation of Fibrinolysis

Middeldorp, S., Tekelenburg, W., van den Ende, A., Tans, G., Prins, M. H., Rosing, J., Buller, H. R., Bouma, B. N., & Meijers, J. C. M. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613959 · Cited by 150 · see citing works

Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.

Poulter, N. R., Cl, C., Farley, T., Marmot, M. G., & Meirik, O. (1998) · PubMed · Cited by 140 · see citing works

High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly

Vlieg, A. V. H., & Rosendaal, F. R. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2003.0543b.x · Cited by 137 · see citing works

Activated protein C resistance determined with a thrombin generation‐based test predicts for venous thrombosis in men and women

Tans, G., Vlieg, A. V. H., Thomassen, S., Curvers, J., Bertina, R. M., Rosing, J., & Rosendaal, F. R. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04443.x · Cited by 133 · see citing works

Resistance to activated protein C in healthy women taking oral contraceptives

Olivieri, O., Friso, S., Manzato, F., Guella, A., Bernardi, F., Lunghi, B., Girelli, D., Azzini, M., Brocco, G., Russo, C. A., et al. (1995) · British Journal of Haematology · doi:10.1111/j.1365-2141.1995.tb05323.x · Cited by 128 · see citing works

Oral progestogen-only contraceptives and cardiovascular risk: Results from the Transnational Study on Oral Contraceptives and the Health of Young Women

Heinemann, L. A. J., Assmann, A., DoMinh, T., & Garbe, E. (1999) · The European Journal of Contraception & Reproductive Health Care · doi:10.3109/13625189909064007 · Cited by 126 · see citing works

Venous thromboembolism amng new users of different oral contraceptives.

Herings, R. M. C., Urquhart, J., & Leufkens, H. G. M. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01257-x · Cited by 115 · see citing works

Determinants of the APTT‐ and ETP‐based APC sensitivity tests

de Visser, M. C. H., Vlieg, A. V. H., Tans, G., et al. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01430.x · Cited by 103 · see citing works

Effects of Hereditary and Acquired Risk Factors of Venous Thrombosis on a Thrombin Generation-Based APC Resistance Test

Curvers, J., Thomassen, S., Rimmer, J. E., et al. (2002) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613145 · Cited by 102 · see citing works

Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol

Goebelsmann, U., Mashchak, C. A., & Mishell, D. R. (1985) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(85)90664-7 · Cited by 99 · see citing works

High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene

Kamphuisen, P. W., Eikenboom, J. C. J., Rosendaal, F. R., Koster, T., Blann, A. D., Vos, H. L., & Bertina, R. M. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03089.x · Cited by 96 · see citing works

Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography

Tchaikovski, S. N., van Vliet, H. A. A. M., Thomassen, S., Bertina, R. M., Rosendaal, F. R., Sandset, P.-M., Helmerhorst, F. M., Tans, G., & Rosing, J. (2007) · Thrombosis and Haemostasis · doi:10.1160/th07-07-0439 · Cited by 93 · see citing works

Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double‐blind, placebo‐controlled trial

Høibraaten, E., Mowinckel, M., de Ronde, H., Bertina, R. M., & Sandset, P. M. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03111.x · Cited by 92 · see citing works

Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens

van Vliet, H. A. A. M., Frölich, M., Thomassen, S., Thomassen, S., Doggen, C. J. M., Rosendaal, F. R., Rosing, J., & Helmerhorst, F. M. (2004) · Human Reproduction · doi:10.1093/humrep/deh612 · Cited by 89 · see citing works

The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study

(2003) · Contraception · doi:10.1016/s0010-7824(02)00476-6 · Cited by 84 · see citing works

Investigations of pharmacokinetics of levonorgestrel to specific consideration of a possible first-pass effect in women

Humpel, M., Wendt, H., Pommerenke, G., Weiβ, C., & Speck, U. (1978) · Contraception · doi:10.1016/0010-7824(78)90012-4 · Cited by 83 · see citing works

Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor

van Vliet, H. A. A. M., Bertina, R. M., Dahm, A. E. A., Rosendaal, F. R., Rosing, J., Sandset, P. M., & Helmerhorst, F. M. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02863.x · Cited by 82 · see citing works

Acquired APC resistance and oral contraceptives: differences between two functional tests

Curvers, J., Thomassen, S., Nicolaes, G. A. F., van Oerle, R., Hamulyák, K., Hemker, H. C., Tans, G., & Rosing, J. (1999) · British Journal of Haematology · doi:10.1111/j.1365-2141.1999.01302.x · Cited by 81 · see citing works

Regulation of TFPI function by protein S

Hackeng, T. M., Maurissen, L. F. A., Castoldi, E., et al. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03363.x · Cited by 78 · see citing works

Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives

Alhenc‐Gelas, M., Plu‐Bureau, G., Guillonneau, S., Kirzin, J.-M., Aiach, M., Ochat, N., & Scarabin, P. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00894.x · Cited by 72 · see citing works

Effects of Oral and Transdermal Hormonal Contraception on Vascular Risk Markers

Johnson, J. V., Lowell, J., Badger, G. J., Rosing, J., Tchaikovski, S. N., & Cushman, M. (2008) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e3181626d1b · Cited by 71 · see citing works

Third-generation oral contraceptive and deep venous thrombosis: From epidemiologic controversy to new insight in coagulation

Vandenbroucke, J. P., Helmerhorst, F. M., Bloemenkamp, K. W. M., & Rosendaal, F. R. (1997) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(97)70289-8 · Cited by 70 · see citing works

Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel

Jick, S. S., Kaye, J. A., Russmann, S., & Jick, H. (2006) · Contraception · doi:10.1016/j.contraception.2006.02.002 · Cited by 69 · see citing works

Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: A cross-over study

Fleischer, K., Vliet, H. A. V., Rosendaal, F. R., Rosing, J., Tchaikovski, S. N., & Helmerhorst, F. M. (2008) · Thrombosis Research · doi:10.1016/j.thromres.2008.04.022 · Cited by 68 · see citing works

Clinical implications. Biological coagulation findings in third-generation oral contraceptives

Conard, J. (1999) · Human Reproduction Update · doi:10.1093/humupd/5.6.672 · Cited by 63 · see citing works

Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor

van Vliet, H. A. A. M., Bertina, R. M., Dahm, A. E. A., et al. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.02863.x · Cited by 63 · see citing works

Pharmacokinetics and Pharmacodynamics of a Transdermal Contraceptive Patch and an Oral Contraceptive

Devineni, D., Skee, D. M., Vaccaro, N. M., Massarella, J. W., Janssens, L., LaGuardia, K. D., & LEUNG, A. T. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006297919 · Cited by 62 · see citing works

Effect of oral contraceptives on the anticoagulant activity of protein S in plasma

Koenen, R., Thomassen, C., Tans, G., Rosing, J., & Hackeng, T. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-11-0762 · Cited by 54 · cited 5× · see citing works

ORAL CONTRACEPTION AND VENOUS THROMBOSIS

Tyler, E. T. (1963) · JAMA · doi:10.1001/jama.1963.03060020091034 · Cited by 52 · see citing works

Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables

Kluft, C., Meijer, P., LaGuardia, K. D., & Fisher, A. C. (2008) · Contraception · doi:10.1016/j.contraception.2007.10.004 · Cited by 42 · see citing works

The fibrinogen gamma (FGG) 10034C>T polymorphism is associated with venous thrombosis

Grünbacher, G., Weger, W., Marx-Neuhold, E., et al. (2007) · Thrombosis Research · doi:10.1016/j.thromres.2007.03.007 · Cited by 39 · see citing works

The association between protein S levels and anticoagulant activity of tissue factor pathway inhibitor type 1

Dahm, A. E. A., Sandset, P. M., & Rosendaal, F. R. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02859.x · Cited by 32 · see citing works

The association between protein S levels and anticoagulant activity of tissue factor pathway inhibitor type 1

Dahm, A. E. A., Sandset, P. M., & Rosendaal, F. R. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.02859.x · Cited by 30 · see citing works

The effect of the levonorgestrel-releasing intrauterine system on the resistance to activated protein C (APC)

Tchaikovski, S., Rosendaal, F. R., Rosing, J., et al. (2009) · Thrombosis and Haemostasis · doi:10.1160/th08-09-0621 · Cited by 26 · see citing works

Factor V Leiden: should all women be screened prior to commencing the contraceptive pill?

Walker, I. D. (1999) · Blood Reviews · doi:10.1016/s0268-960x(99)90019-x · Cited by 25 · see citing works

Contraception in the prepill era

Connell, E. (1999) · Contraception · doi:10.1016/s0010-7824(98)00130-9 · Cited by 24 · see citing works

Estrogens, selective estrogen receptor modulators, and a selective estrogen receptor down-regulator inhibit endothelial production of tissue factor pathway inhibitor 1

Dahm, A. E. A., Iversen, N., Birkenes, B., Ree, A. H., & Sandset, P. M. (2006) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-6-40 · Cited by 22 · see citing works

Lack of association between venous thrombosis and subsequent malignancy in a retrospective cohort study in young patients

Subir�, M., Mateo, J., Souto, J. C., Alt�s, A., & Fontcuberta, J. (1999) · American Journal of Hematology · doi:10.1002/(sici)1096-8652(199903)60:3 · Cited by 22 · see citing works

Clinical experience with the recently developed progestogens.

Skouby, S. O., & Kr, P. (1991) · PubMed · Cited by 11 · see citing works

Influence of the third generation pill controversy on prescriptions for oral contraceptives among first time users: population based study

den Berg, L. D. J., Tobi, H., Bijker, B., et al. (2003) · BMJ · doi:10.1136/bmj.326.7383.254 · Cited by 10 · see citing works

Pregnancy‐associated changes in the hemostatic system in wild‐type and factor V Leiden mice

Tchaikovski, S. N., van Vlijmen, B. J. M., Cleuren, A. C. A., et al. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03240.x · Cited by 9 · see citing works

Endogenous or exogenous coagulation factor level and the response to activated protein C

Gennari, L., Blanco, A. N., Domínguez, M. P., et al. (2005) · Thrombosis Research · doi:10.1016/j.thromres.2005.07.022 · Cited by 6 · see citing works

Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke

Roach, R. E. J., Helmerhorst, F. M., Lijfering, W. M., Stijnen, T., Algra, A., & Dekkers, O. M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011054.pub2 · Cited by 299 · see citing works

Estrogen and thrombosis: a bench to bedside review

Abou-Ismail, M. Y., Citla Sridhar, D., & Nayak, L. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.05.008 · Cited by 261 · see citing works

Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters

Douxfils, J., Klipping, C., Duijkers, I., Kinet, V., Mawet, M., Maillard, C., Jost, M., Rosing, J., & Foidart, J.-M. (2020) · Contraception · doi:10.1016/j.contraception.2020.08.015 · Cited by 120 · see citing works

Nonoral combined hormonal contraceptives and thromboembolism: a systematic review

Tepper, N. K., Dragoman, M. V., Gaffield, M. E., & Curtis, K. M. (2017) · Contraception · doi:10.1016/j.contraception.2016.10.005 · Cited by 73 · see citing works

Estrogen and thrombosis: controversies and common sense

DeLoughery, T. G. (2011) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-011-9178-0 · Cited by 21 · see citing works

Sustained intrauterine release of levonorgestrel over five years

Nilsson, C. G., Lähteenmäki, P. L. A., Luukkainen, T., & Robertson, D. N. (1986) · Fertility and Sterility · doi:10.1016/s0015-0282(16)49397-0 · Cited by 78 · see citing works

Pharmacokinetics of a single oral dose of 1.5-mg levonorgestrel when administered as 750-μg tablets or as 30-μg minipills

Devoto, L., Espinoza, A., Muñoz, A., et al. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.12.088 · Cited by 3 · see citing works

Clinical observation of compound levonorgestrel for emergency contraception

Jianhua, R. (2012) · China Medicine and Pharmacy

Erratum to “Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system” [Contraception 86 (2012) 345–349]

Seeber, B., Ziehr, S. C., Gschlieβer, A., et al. (2013) · Contraception · doi:10.1016/j.contraception.2013.01.005

TISSUE CONCENTRATIONS OF LEVONORGESTREL IN WOMEN USING A LEVONORGESTREL‐RELEASING IUD

Nilsson, C. G., Haukkamaa, M., Vierola, H., Luukkainen, T., & Arcangeli, P. (1982) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1982.tb01625.x · Cited by 215 · see citing works